{"id":"NCT00394901","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","briefTitle":"A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Postherpetic Neuralgia","officialTitle":"A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study To Evaluate Efficacy And Safety Of Pregabalin In The Treatment Of Postherpetic Neuralgia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-09","primaryCompletion":"2007-11","completion":"2007-11","firstPosted":"2006-11-02","resultsPosted":"2009-02-27","lastUpdate":"2021-02-09"},"enrollment":372,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Neuralgia, Postherpetic"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Pregabalin","otherNames":[]},{"type":"DRUG","name":"Pregabalin","otherNames":[]},{"type":"DRUG","name":"Pregabalin","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Pregabalin 150mg/day","type":"EXPERIMENTAL"},{"label":"Pregabalin 300mg/day","type":"EXPERIMENTAL"},{"label":"Pregabalin 600mg/day","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate efficacy and safety of pregabalin in the treatment of postherpetic neuralgia in a dose-ranging manner.","primaryOutcome":{"measure":"Mean Pain Scores at Endpoint","timeFrame":"Week13/discontinuation","effectByArm":[{"arm":"Placebo","deltaMin":5.12,"sd":0.19},{"arm":"Pregabalin 150 mg/Day","deltaMin":4.81,"sd":0.2},{"arm":"Pregabalin 300 mg/Day","deltaMin":4.26,"sd":0.2},{"arm":"Pregabalin 600 mg/Day","deltaMin":4.49,"sd":0.19}],"pValues":[{"comp":"OG000 vs OG001","p":"0.262"},{"comp":"OG000 vs OG002","p":"0.002"},{"comp":"OG000 vs OG003","p":"0.019"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":5},"locations":{"siteCount":39,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0081120&StudyName=A%2013-Week%2C%20Randomized%2C%20Double-Blind%2C%20Multicenter%2C%20Placebo-Controlled%20Study%20Of%20Pregabalin%20For%20Postherpetic%20Neuralgia"]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":98},"commonTop":["Dizziness","Somnolence","Constipation","Oedema peripheral","Nasopharyngitis"]}}